Why Urologists Get Sued: Missed GU Cancers, Ureteral Injuries, and the Consent That Doubled the Odds

By John Mahoney · June 2026 · 8 min read

Urology is one of the most-sued specialties in medicine, yet also one of the more defensible when the chart is clean. That tension — high claim frequency, moderate per-claim payouts — is the single most important thing to understand about a urology case before you take it or defend it. Treat a urology matter like a neurosurgery or OB matter and you will mis-price it; treat it like a routine surgical claim and you will miss the small set of fact patterns that actually drive the dollars.

This guide is written for plaintiff and defense med-mal attorneys screening urology claims. It covers the frequency-and-severity reality, the allegation buckets that account for the majority of claims, the genitourinary misses and intraoperative injuries that drive payouts, and the contributing factors — especially informed consent and documentation — that separate a payable case from a defensible one.

Disclaimer: This article is for informational purposes only and does not constitute legal advice or a medical opinion. Closed-claims figures are drawn from insurer and registry datasets that span different eras and methodologies; some are older or come from trainee-involved subsets and should be treated as directional. Always evaluate the specific record and retain a qualified expert.

The Frequency-and-Severity Reality

By claim frequency, urology sits in the high-risk surgical tier. The widely cited Jena et al. analysis (NEJM 2011) reported roughly a 10.5% annual claim frequency for urologists — about 7th-highest of 25 specialties and well above the all-physician average near 7.4% per year. In practical terms, virtually every urologist is named in at least one claim over a career.

Severity is where urology diverges from its high-frequency surgical peers. Reported average paid urology claims have historically run below the all-specialty average — on the order of the low-to-mid $200,000s in the datasets cited, with prostatectomy claims among the more expensive subgroups. One confidence caveat: much of the core urology indemnity data is older (studies spanning roughly 1985–2007), and the higher figures that circulate often come from trainee-involved subsets that skew upward. Treat the precise dollar figures as directional, not as a verdict predictor.

The takeaway is structural: volume of claims does not equal dollars at risk. A high-frequency, moderate-payout specialty rewards disciplined triage — the claims worth pursuing, and the ones defense counsel should worry about, cluster in a recognizable set of fact patterns, not across the whole docket.

The Dominant Allegation Types

Urology claims split, like other surgical specialties, between technical-performance allegations and diagnostic allegations — but in urology those two categories are unusually intertwined. In a large closed-claims series (Sicat/Benway, J Urol, covering thousands of claims from 1985–2007), improper performance of surgery or a procedure and diagnostic error together accounted for about 51% of all urology claims. The rest distribute across:

• Surgical/procedural treatment as the primary allegation. Consistent with the broader surgical pattern, the substantial majority of surgeon claims list surgical treatment, with improper performance the modal sub-allegation.
• Diagnostic error — failure or delay in diagnosis, concentrated heavily in genitourinary malignancy.
• Failure to monitor or manage the case — a consistent third-ranked category in the closed-claims series.
• Lack of informed consent, which we treat separately below because it functions less as a stand-alone theory and more as a payment multiplier.

The practical move on intake is to identify early which side of the technical/diagnostic axis a case falls on: a procedural case turns on whether a realized complication was a disclosed, competently managed risk or a negligent intraoperative injury; a diagnostic case turns on whether an abnormal result was tracked and acted on. The merit logic differs, and so does the expert you will need.

The Cannot-Miss Conditions and Failures

A handful of fact patterns drive a disproportionate share of urology severity. These are the flags worth screening for on both sides:

• Missed or delayed genitourinary cancer. This is the dominant diagnostic-error driver in urology — prostate, bladder, kidney/renal, and testicular cancer. Urologic oncology accounted for roughly 28% of claims in one survey of practicing urologists. The recurring failure is not the initial visit; it is the abnormal PSA, the suspicious imaging finding, the atypical cytology, or the biopsy result that was never tracked to closure.
• Iatrogenic ureteral injury — transection or ligation, frequently during endourologic or pelvic surgery. The defensibility hinges on timing: delayed recognition dramatically increases the payout. An injury identified and repaired intraoperatively is a very different case from one discovered days later when the patient returns septic.
• Endoscopic and endourologic complications — cystoscopy with ureteral stent placement or exchange, ureteroscopic lithotripsy, percutaneous stone extraction. Endourology represented roughly 12% of claims in the survey data.
• Retained surgical items — including retained ureteral stents. These are near-automatic liability. A stent that was placed and never removed is a documentation-and-tracking failure that is very hard to defend.
• Prostatectomy and post-procedure organ injury — the most expensive subgroup, including bowel perforation, urethral damage, and other adjacent-structure injury.

A shortcut applies within urology: a documented delay in acting on an abnormal cancer signal, a delayed-recognition organ injury, or a retained item should each elevate merit immediately on a plaintiff intake — and is exactly where defense counsel should concentrate the early workup.

Contributing Factors: Where Cases Are Actually Won and Lost

The allegation tells you the theory. The contributing factors tell you whether the claim gets paid. In urology, four recur:

• Technical performance and surgical skill. Improper performance was cited in roughly 60% of surgical cases in the Candello data, and intraoperative negligence appeared in a large majority of surgical urology claims in endourology series. This is the liability core of the procedural cases.
• Clinical judgment and decision-making. Overlooked findings and failures to order or act on diagnostic tests carry the greatest financial severity in the Candello surgical data — consistent with the broader rule that diagnostic-error claims pay the most.
• Informed-consent deficiency. This is the urology payment lever. Inadequate consent has been associated with roughly double the odds of a paid claim (reported on the order of a 114% increase), and consent deficiencies appeared in roughly 31% of trainee-involved cases. A realized complication that was a disclosed, known risk is defense-favorable; the same complication, undisclosed, becomes payable.
• Documentation gaps. Across the Candello dataset, documentation deficiencies contribute to roughly one in five malpractice cases. In urology, thin operative notes and missing consent records rarely create the liability — they remove the defense.

That documentation-and-communication pattern is not unique to urology: across nearly every specialty, these are defensibility levers rather than liability levers. For defense counsel, a thin chart is a problem to surface early; for plaintiff counsel, the same gaps are leverage.

What Separates a Strong Case From a Weak One

Both sides are really asking the same question: was the bad outcome a negligent act, or a known complication competently disclosed and managed? In urology, the answer turns on three things.

Was the complication a disclosed, known risk?

This is the hinge. Ureteral injury, organ injury, and many endourologic complications are recognized risks of competently performed procedures. If the consent discussion is documented and the risk disclosed, the case tilts defense. If consent is thin or absent, the same complication tilts plaintiff — because consent deficiency roughly doubles paid odds. Score consent adequacy heavily on intake.

Was the injury recognized and addressed in time?

Delayed recognition is the severity multiplier in urology. An intraoperatively recognized and repaired ureteral injury is defensible; a missed one discovered after the patient deteriorates is not. The record's timeline — when the injury occurred, when it was suspected, when imaging or stenting followed — often decides the case. A causation chain that maps the negligent act to the harm, link by link, is what a strong urology case needs and a weak one cannot build. For the diagnostic cases, the parallel question is the closed loop: was the abnormal PSA, imaging finding, cytology, or biopsy result communicated, followed up, and acted on? A documented tracking failure is among the strongest systemic merit signals in any specialty; a clean, closed loop is among the strongest defenses.

Will the expert survive the next gate?

The expert who supports your merit theory today is the one the other side will try to exclude tomorrow. Because urology pairs a surgical-technical theory with a diagnostic theory, the same specialty-match and reliability questions that govern the certificate of merit feed directly into a later Daubert and FRE 702 challenge — pressure-test the opinion for both at once. And because severity here is moderate relative to high-payout specialties, run the realistic damages picture early; our damages calculator helps frame exposure against the moderate per-claim payouts urology actually generates, so neither side over-values a high-frequency, modest-dollar claim.

Bottom Line

Urologists are sued often but pay moderately, which makes disciplined triage the whole game. The dollars concentrate in a recognizable set of fact patterns: missed or delayed genitourinary cancer where an abnormal result was never tracked, ureteral or organ injury recognized too late, and retained items. Across all of them, informed-consent adequacy and documentation are the levers that move a claim from defensible to payable — consent deficiency alone roughly doubles paid odds. Screen for the disclosed-risk question, the recognition-timeline question, and the closed-loop question, and you will price a urology case correctly from whichever side you sit on.

Questions? Contact us at [email protected] or (856) 979-6525

🔎 Screening a case in a different specialty? Browse all 70 specialty malpractice-risk guides in one place — Why Doctors Get Sued: Malpractice Risk by Specialty →